merged_drug-prices-medicare.txt
<question_number>1</question_number>
<answer>The $2,000 annual cap takes effect in 2025, while the new negotiated prices take effect in 2026.</answer>
<question_number>2</question_number>
<answer>The Project 2025 playbook suggests that the drug price negotiation program could be repealed if Republicans gain full control of the government.</answer>
<question_number>3</question_number>
<answer>Kamala Harris cast the tiebreaking vote for the legislation enabling the negotiation program, and she has prioritized drug pricing reforms in her early presidential campaign.</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>$730</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Fiasp and NovoLog insulin products (at $119 per month, requiring 17 refills to reach $2,000).</answer>
<question_number>8</question_number>
<answer>Approximately 71.5% (Imbruvica: $9,319, Stelara: $4,695, Enbrel: $2,355; total: $16,369 out of $22,479).</answer>
<question_number>9</question_number>
<answer>$19 (Jardiance: $197, Farxiga: $178).</answer>
<question_number>10</question_number>
<answer>$16,844 (Johnson & Johnson: Xarelto $197, Imbruvica $9,319, Stelara $4,695; Merck: Januvia $113; Bristol Myers Squibb: Eliquis $231; AstraZeneca: Farxiga $178; Amgen: Enbrel $2,355).</answer>